1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disease Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Market by Application
1.3.1 Global Metabolic Disease Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disease Drugs Market Perspective (2017-2028)
2.2 Metabolic Disease Drugs Growth Trends by Region
2.2.1 Metabolic Disease Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metabolic Disease Drugs Historic Market Size by Region (2017-2022)
2.2.3 Metabolic Disease Drugs Forecasted Market Size by Region (2023-2028)
2.3 Metabolic Disease Drugs Market Dynamics
2.3.1 Metabolic Disease Drugs Industry Trends
2.3.2 Metabolic Disease Drugs Market Drivers
2.3.3 Metabolic Disease Drugs Market Challenges
2.3.4 Metabolic Disease Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disease Drugs Players by Revenue
3.1.1 Global Top Metabolic Disease Drugs Players by Revenue (2017-2022)
3.1.2 Global Metabolic Disease Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Metabolic Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disease Drugs Revenue
3.4 Global Metabolic Disease Drugs Market Concentration Ratio
3.4.1 Global Metabolic Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disease Drugs Revenue in 2021
3.5 Metabolic Disease Drugs Key Players Head office and Area Served
3.6 Key Players Metabolic Disease Drugs Product Solution and Service
3.7 Date of Enter into Metabolic Disease Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disease Drugs Breakdown Data by Type
4.1 Global Metabolic Disease Drugs Historic Market Size by Type (2017-2022)
4.2 Global Metabolic Disease Drugs Forecasted Market Size by Type (2023-2028)
5 Metabolic Disease Drugs Breakdown Data by Application
5.1 Global Metabolic Disease Drugs Historic Market Size by Application (2017-2022)
5.2 Global Metabolic Disease Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metabolic Disease Drugs Market Size (2017-2028)
6.2 North America Metabolic Disease Drugs Market Size by Country (2017-2022)
6.3 North America Metabolic Disease Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Metabolic Disease Drugs Market Size (2017-2028)
7.2 Europe Metabolic Disease Drugs Market Size by Country (2017-2022)
7.3 Europe Metabolic Disease Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disease Drugs Market Size (2017-2028)
8.2 Asia-Pacific Metabolic Disease Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Metabolic Disease Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Metabolic Disease Drugs Market Size (2017-2028)
9.2 Latin America Metabolic Disease Drugs Market Size by Country (2017-2022)
9.3 Latin America Metabolic Disease Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disease Drugs Market Size (2017-2028)
10.2 Middle East & Africa Metabolic Disease Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Metabolic Disease Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Metabolic Disease Drugs Introduction
11.1.4 Merck Revenue in Metabolic Disease Drugs Business (2017-2022)
11.1.5 Merck Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Metabolic Disease Drugs Introduction
11.2.4 Novartis Revenue in Metabolic Disease Drugs Business (2017-2022)
11.2.5 Novartis Recent Development
11.3 Takeda Pharmaceutical
11.3.1 Takeda Pharmaceutical Company Detail
11.3.2 Takeda Pharmaceutical Business Overview
11.3.3 Takeda Pharmaceutical Metabolic Disease Drugs Introduction
11.3.4 Takeda Pharmaceutical Revenue in Metabolic Disease Drugs Business (2017-2022)
11.3.5 Takeda Pharmaceutical Recent Development
11.4 Astra Zeneca
11.4.1 Astra Zeneca Company Detail
11.4.2 Astra Zeneca Business Overview
11.4.3 Astra Zeneca Metabolic Disease Drugs Introduction
11.4.4 Astra Zeneca Revenue in Metabolic Disease Drugs Business (2017-2022)
11.4.5 Astra Zeneca Recent Development
11.5 Beohrigher Ingelheim
11.5.1 Beohrigher Ingelheim Company Detail
11.5.2 Beohrigher Ingelheim Business Overview
11.5.3 Beohrigher Ingelheim Metabolic Disease Drugs Introduction
11.5.4 Beohrigher Ingelheim Revenue in Metabolic Disease Drugs Business (2017-2022)
11.5.5 Beohrigher Ingelheim Recent Development
11.6 KOWA
11.6.1 KOWA Company Detail
11.6.2 KOWA Business Overview
11.6.3 KOWA Metabolic Disease Drugs Introduction
11.6.4 KOWA Revenue in Metabolic Disease Drugs Business (2017-2022)
11.6.5 KOWA Recent Development
11.7 Kythera
11.7.1 Kythera Company Detail
11.7.2 Kythera Business Overview
11.7.3 Kythera Metabolic Disease Drugs Introduction
11.7.4 Kythera Revenue in Metabolic Disease Drugs Business (2017-2022)
11.7.5 Kythera Recent Development
11.8 Fuji yakuhin
11.8.1 Fuji yakuhin Company Detail
11.8.2 Fuji yakuhin Business Overview
11.8.3 Fuji yakuhin Metabolic Disease Drugs Introduction
11.8.4 Fuji yakuhin Revenue in Metabolic Disease Drugs Business (2017-2022)
11.8.5 Fuji yakuhin Recent Development
11.9 LG Life Science
11.9.1 LG Life Science Company Detail
11.9.2 LG Life Science Business Overview
11.9.3 LG Life Science Metabolic Disease Drugs Introduction
11.9.4 LG Life Science Revenue in Metabolic Disease Drugs Business (2017-2022)
11.9.5 LG Life Science Recent Development
11.10 Metsubishi Tanabe Pharma
11.10.1 Metsubishi Tanabe Pharma Company Detail
11.10.2 Metsubishi Tanabe Pharma Business Overview
11.10.3 Metsubishi Tanabe Pharma Metabolic Disease Drugs Introduction
11.10.4 Metsubishi Tanabe Pharma Revenue in Metabolic Disease Drugs Business (2017-2022)
11.10.5 Metsubishi Tanabe Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Metabolic Disease Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Glycogen Metabolism Disease Drug
Table 3. Key Players of Lipid Metabolism Disease Drug
Table 4. Key Players of Amino Acid Metabolism Drug
Table 5. Key Players of Other
Table 6. Global Metabolic Disease Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Metabolic Disease Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Metabolic Disease Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Metabolic Disease Drugs Market Share by Region (2017-2022)
Table 10. Global Metabolic Disease Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Metabolic Disease Drugs Market Share by Region (2023-2028)
Table 12. Metabolic Disease Drugs Market Trends
Table 13. Metabolic Disease Drugs Market Drivers
Table 14. Metabolic Disease Drugs Market Challenges
Table 15. Metabolic Disease Drugs Market Restraints
Table 16. Global Metabolic Disease Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Metabolic Disease Drugs Market Share by Players (2017-2022)
Table 18. Global Top Metabolic Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2021)
Table 19. Ranking of Global Top Metabolic Disease Drugs Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Metabolic Disease Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Metabolic Disease Drugs Product Solution and Service
Table 23. Date of Enter into Metabolic Disease Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metabolic Disease Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Metabolic Disease Drugs Revenue Market Share by Type (2017-2022)
Table 27. Global Metabolic Disease Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Metabolic Disease Drugs Revenue Market Share by Type (2023-2028)
Table 29. Global Metabolic Disease Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Metabolic Disease Drugs Revenue Market Share by Application (2017-2022)
Table 31. Global Metabolic Disease Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Metabolic Disease Drugs Revenue Market Share by Application (2023-2028)
Table 33. North America Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 34. North America Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 35. Europe Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 36. Europe Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 37. Asia-Pacific Metabolic Disease Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 38. Asia-Pacific Metabolic Disease Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 39. Latin America Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 40. Latin America Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 41. Middle East & Africa Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 42. Middle East & Africa Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 43. Merck Company Detail
Table 44. Merck Business Overview
Table 45. Merck Metabolic Disease Drugs Product
Table 46. Merck Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 47. Merck Recent Development
Table 48. Novartis Company Detail
Table 49. Novartis Business Overview
Table 50. Novartis Metabolic Disease Drugs Product
Table 51. Novartis Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 52. Novartis Recent Development
Table 53. Takeda Pharmaceutical Company Detail
Table 54. Takeda Pharmaceutical Business Overview
Table 55. Takeda Pharmaceutical Metabolic Disease Drugs Product
Table 56. Takeda Pharmaceutical Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 57. Takeda Pharmaceutical Recent Development
Table 58. Astra Zeneca Company Detail
Table 59. Astra Zeneca Business Overview
Table 60. Astra Zeneca Metabolic Disease Drugs Product
Table 61. Astra Zeneca Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 62. Astra Zeneca Recent Development
Table 63. Beohrigher Ingelheim Company Detail
Table 64. Beohrigher Ingelheim Business Overview
Table 65. Beohrigher Ingelheim Metabolic Disease Drugs Product
Table 66. Beohrigher Ingelheim Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 67. Beohrigher Ingelheim Recent Development
Table 68. KOWA Company Detail
Table 69. KOWA Business Overview
Table 70. KOWA Metabolic Disease Drugs Product
Table 71. KOWA Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 72. KOWA Recent Development
Table 73. Kythera Company Detail
Table 74. Kythera Business Overview
Table 75. Kythera Metabolic Disease Drugs Product
Table 76. Kythera Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 77. Kythera Recent Development
Table 78. Fuji yakuhin Company Detail
Table 79. Fuji yakuhin Business Overview
Table 80. Fuji yakuhin Metabolic Disease Drugs Product
Table 81. Fuji yakuhin Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 82. Fuji yakuhin Recent Development
Table 83. LG Life Science Company Detail
Table 84. LG Life Science Business Overview
Table 85. LG Life Science Metabolic Disease Drugs Product
Table 86. LG Life Science Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 87. LG Life Science Recent Development
Table 88. Metsubishi Tanabe Pharma Company Detail
Table 89. Metsubishi Tanabe Pharma Business Overview
Table 90. Metsubishi Tanabe Pharma Metabolic Disease Drugs Product
Table 91. Metsubishi Tanabe Pharma Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 92. Metsubishi Tanabe Pharma Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disease Drugs Market Share by Type: 2021 VS 2028
Figure 2. Glycogen Metabolism Disease Drug Features
Figure 3. Lipid Metabolism Disease Drug Features
Figure 4. Amino Acid Metabolism Drug Features
Figure 5. Other Features
Figure 6. Global Metabolic Disease Drugs Market Share by Application in 2021 & 2028
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Metabolic Disease Drugs Report Years Considered
Figure 10. Global Metabolic Disease Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Metabolic Disease Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Metabolic Disease Drugs Market Share by Region: 2021 VS 2028
Figure 13. Global Metabolic Disease Drugs Market Share by Players in 2021
Figure 14. Global Top Metabolic Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Metabolic Disease Drugs Revenue in 2021
Figure 16. North America Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Metabolic Disease Drugs Market Share by Country (2017-2028)
Figure 18. United States Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Metabolic Disease Drugs Market Share by Country (2017-2028)
Figure 22. Germany Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Metabolic Disease Drugs Market Share by Region (2017-2028)
Figure 30. China Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Metabolic Disease Drugs Market Share by Country (2017-2028)
Figure 38. Mexico Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Metabolic Disease Drugs Market Share by Country (2017-2028)
Figure 42. Turkey Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Merck Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 45. Novartis Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 46. Takeda Pharmaceutical Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 47. Astra Zeneca Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 48. Beohrigher Ingelheim Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 49. KOWA Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 50. Kythera Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 51. Fuji yakuhin Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 52. LG Life Science Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 53. Metsubishi Tanabe Pharma Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
